

# Peptide for Regulation of Urokinase Plasminogen Activator and Method of Optimizing Therapeutic Efficacy

## Abstract of Disclosure

The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcnPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents.

